Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments
Swayampakula Ramakanth has issued a Buy rating for Bicycle Therapeutics, citing strong upside potential due to upcoming clinical updates and favorable financial conditions. The company plans to provide a significant clinical update on zelenectide pevedotin in metastatic urothelial cancer in Q1 2026, which may improve Phase 3 study designs. Currently trading below cash value, Bicycle Therapeutics shows a compelling risk/reward profile, with a 12-month price target of $33 based on a risk-adjusted valuation. Barclays also maintains a Buy rating with a $15 price target.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight the potential and current valuation of Bicycle Therapeutics. The company has announced a timeline shift for a significant clinical update regarding zelenectide pevedotin in metastatic urothelial cancer, with the update now expected in the first quarter of 2026. This update will include feedback from multiple regulatory agencies, which could enhance the design of a global Phase 3 study to meet various regulatory requirements, thereby increasing the potential for successful outcomes.
Additionally, Bicycle Therapeutics is trading below its cash value, presenting a compelling risk/reward opportunity. At the end of the third quarter of 2025, the company had substantial cash reserves, and its recent financial performance exceeded consensus expectations. The analyst’s valuation model, which includes a risk-adjusted net present value analysis, supports a 12-month price target of $33, indicating significant upside potential from the current trading price.
In another report released today, Barclays also maintained a Buy rating on the stock with a $15.00 price target.
